1. Home
  2. COCH vs BOLD Comparison

COCH vs BOLD Comparison

Compare COCH & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

N/A

Current Price

$6.26

Market Cap

49.9M

Sector

Finance

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$2.46

Market Cap

54.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
COCH
BOLD
Founded
1995
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
49.9M
54.5M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
COCH
BOLD
Price
$6.26
$2.46
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $21.67
N/A
AVG Volume (30 Days)
12.7K
★ 163.8K
Earning Date
11-05-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
17.45
★ 32.47
EPS
★ N/A
N/A
Revenue
★ $241,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17.14
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 7.11
N/A
52 Week Low
$5.36
$0.96
52 Week High
$66.06
$3.16

Technical Indicators

Market Signals
Indicator
COCH
BOLD
Relative Strength Index (RSI) 43.14 44.24
Support Level $5.36 $2.37
Resistance Level $40.14 $2.71
Average True Range (ATR) 1.89 0.15
MACD -0.42 0.02
Stochastic Oscillator 2.08 39.02

Price Performance

Historical Comparison
COCH
BOLD

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: